Goldman Adds Alcon to 'Recommended List'

Analyst Katherine Breeds likes the specialty drug maker's industry metrics and earnings quality

Goldman Sachs added Alcon (ACL ) to its recommended list; the stock was previously rated market outperform.

Analyst Katherine Breeds says Alcon represents an attractive investment opportunity. She notes the company earns strong marks when assessed on a relative basis to other specialty pharmaceutical companies in her universe based on industry metrics, value creation and earnings per share quality.

She raised her $1.55 2002 earnings per share estimate to $1.56, and upped the $1.71 2003 earnings per share estimate to $1.79.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE